Table 1.
Patient Demographics in Current Study
| Characteristic | 15mg/kg Crenezumab IV Every 4 Weeks, n = 37 | 300mg Crenezumab SC Every 2 Weeks, n = 37 | Placebo, n = 32 |
|---|---|---|---|
| Age, yr (SD) | 70.8 (6.9) | 68.1 (8) | 68.7 (7.7) |
| Sex, F (%) | 19 (51.4%) | 20 (54.1%) | 17 (53.1%) |
| MMSE mean score (SD) | 22.1 (2.9) | 22.2 (2.8) | 22.2 (2.4) |
| MMSE score 22–26, n (%) | 21 (56.8%) | 20 (54.1%) | 17 (53.1%) |
| APOE ε4 carriers, n (%) | 26 (70.3%) | 27 (73%) | 27 (84.4%) |
| ADAS‐Cog12 mean score (SD) | 27.6 (9.7) | 28.1 (9.7) | 27.1 (7.9) |
| CDR‐SB mean score (SD) | 4.1 (1.7) | 4.3 (2.0) | 4.2 (1.5) |
| ADCS‐ADL mean score (SD) | 68.2 (5.9) | 65.1 (11.1) | 67.4 (6.6) |
ADAS‐Cog12 = Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS‐ADL = Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory; CDR‐SB = Clinical Dementia Rating–Sum of Boxes; F = female; IV = intravenous; MMSE = Mini‐Mental State Examination; SC = subcutaneous; SD = standard deviation.